Clinical Trial Update: Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant ) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pyrotinib in combination with fulvestrant in HR+/HER2+ metastatic breast cancer is in progress, with status currently unknow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN